Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Expenses: 2022-2025

Historic Operating Expenses for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $9.7 million.

  • InMed Pharmaceuticals' Operating Expenses fell 0.20% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year increase of 9.25%. This contributed to the annual value of $9.7 million for FY2025, which is 3.83% up from last year.
  • InMed Pharmaceuticals' Operating Expenses amounted to $9.7 million in FY2025, which was up 3.83% from $9.3 million recorded in FY2024.
  • InMed Pharmaceuticals' Operating Expenses' 5-year high stood at $17.8 million during FY2022, with a 5-year trough of $9.3 million in FY2024.
  • In the last 3 years, InMed Pharmaceuticals' Operating Expenses had a median value of $9.7 million in 2025 and averaged $9.6 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Operating Expenses tumbled by 44.80% in 2023, and later climbed by 3.83% in 2025.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Operating Expenses stood at $17.8 million in 2022, then plummeted by 44.80% to $9.8 million in 2023, then dropped by 5.42% to $9.3 million in 2024, then rose by 3.83% to $9.7 million in 2025.